Загрузка...
The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials
As the drug development pipeline for Duchenne muscular dystrophy (DMD) rapidly advances, clinical trial outcomes need to be optimized. Effective assessment of disease burden, natural history progression, and response to therapy in clinical trials for Duchenne muscular dystrophy are critical factors...
Сохранить в:
| Опубликовано в: : | Neurotherapeutics |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007477/ https://ncbi.nlm.nih.gov/pubmed/31879850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-019-00825-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|